Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Treatment of neuropathic pain (NP) symptoms associated with multiple sclerosis (MS) is frequently insufficient. Yet, cannabis is still rarely offered for treatment of pain. This clinical trial aimed at showing the positive benefit-risk ratio of dronabinol. Two hundred forty MS patients with central NP entered a 16-weeks placebo-controlled phase-III study followed by a 32-weeks open-label period. One hundred patients continued therapy for overall up to 119 weeks. Primary endpoint was change of pain intensity on the 11-point Numerical Rating Scale over a 16-weeks treatment period. Safety was assessed on the basis of adverse reactions (ARs), signs of dependency and abuse. Pain intensity during 16-weeks dronabinol and placebo treatment was reduced by 1.92 and 1.81 points without significant difference in between (p = 0.676). Although the proportion of patients with ARs was higher under dronabinol compared to placebo (50.0 vs. 25.9%), it decreased during long-term use of dronabinol (26%). No signs of drug abuse and only one possible case of dependency occurred. The trial results demonstrate that dronabinol is a safe long-term treatment option.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Treede (2008) · doi:10.1212/01.wnl.0000282763.29778.59 · Cited by 2,746
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Dworkin, R. H., O'Connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., LeBel, A. A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,325
Bullinger, M. (1995) · Social Science & Medicine · doi:10.1016/0277-9536(95)00115-n · Cited by 763
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Cited by
Items 101–135 of 135
McDonagh, M. S., Wagner, J., Ahmed, A. Y., Morasco, B. J., Kansagara, D. L., & Chou, R. (2020) · Europe PMC (PubMed Central) · Cited by 1
McDonagh, M. S., Wagner, J., Ahmed, A. Y., Morasco, B. J., Kansagara, D. L., & Chou, R. (2021) · doi:10.23970/ahrqepccerplantpain3 · Cited by 1
Lambert, D. M. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0376050 · Cited by 1
“37 1 [177] 2 [165] 3 [178] 4 [166] 5 [161] 6 [162] 7 [164] 8 [163] 9[179]”
Chou, R., Wagner, J., Ahmed, A. Y., Morasco, B. J., Kansagara, D. L., & Selph, S. (2022) · doi:10.23970/ahrqepccannabissurveillance3 · Cited by 1
Trattamento farmacologico dei dolori neuropatici
Tosti, G., & Attal, N. (2021) · EMC - Neurologia · doi:10.1016/s1634-7072(21)45318-3
Understanding the Evidence for Medical Cannabinoids for the Treatment of Chronic Pain
Rougraff, S. (2022) · Journal of Student Research · doi:10.47611/jsr.v10i2.1226
Pronounced state-level variation in prescription cannabinoids to Medicaid patientsPreprint
Liu, E. Y., McCall, K. L., & Piper, B. J. (2022) · medRxiv · doi:10.1101/2022.06.04.22275992
Cannabinoides en dolor neuropático: luces y sombras
Afonso, A. S. (2022) · Revista de la Sociedad Española del Dolor · doi:10.20986/resed.2022.4027/2022 · Cited by 2
McDonagh, M. S., Wagner, J., Ahmed, A. Y., Morasco, B. J., Kansagara, D. L., & Chou, R. (2022) · doi:10.23970/ahrqepccannabissurveillance2
Systematic Review on Acute Treatments for Episodic Migraine: Surveillance Report 1
Singh, R. B. H., VanderPluym, J. H., Hasan, B., Farah, M. H., Viola, K. E., Saadi, S. M., Shah, S. H., Nayfeh, T., Prokop, L. J., Murad, M., et al. (2022) · doi:10.23970/ahrqepcmigrainesurveillance1 · Cited by 1
О.Д., П. О. О. Ш. (2022) · Український медичний часопис · doi:10.32471/umj.1680-3051.152.236002
Dronabinol Useful for Chronic Pain: A Case Report
Agnello, R. N. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.49.007763 · Cited by 1
Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. M. (2023) · Current Physical Medicine and Rehabilitation Reports · doi:10.1007/s40141-023-00416-4
Tetrahydrocannabinol in Pediatrics: Room for Improvement?
de Gier, C., Scharinger, C., Stark, R., Steurer, P., & Klier, C. M. (2023) · Medical Cannabis and Cannabinoids · doi:10.1159/000533607
“Furthermore, Δ 9-THC is administered in patients with chemotherapy-associated nausea and vomiting [13, 14] and shows an effect in chronic and neuropathic pain patients [15, 16].”
BackgroundExploring the efficacy of cannabinoids in the management of multiple sclerosis
Rykucka, A., Zozula, N., Wąs, M., Kiełbasa, J., Kowalczyk, A., Bil, K., Ślesicka, I., Latała, A., Tomczewska, Z., & Przestrzelska, M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.74.52563
“Dronabinol proves to be effective and safe in pain management in MS patients in long-term treatment 52 .”
BackgroundMiscellaneous Psychotropic Drugs
Masson, S., Bleuer‐Elsner, S., Muller, G., Médam, T., Chevallier, J., & Gaultier, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-53012-8_26
Cannabinoides y dolor PARTE II
Regueras, E., Torres, L. M., & Velázquez, I. (2024) · Multidisciplinary Pain Journal · doi:10.20986/mpj.2024.1053/2023
Fenton, C., & Fung, S. S.-P. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01197-7
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517185
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517173
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517164
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517176
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517179
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517167
Bleuer‐Elsner, S., Masson, S., Lacoste, M., & Muller, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-06260-4_25
Bellis, J., Monk, L., Jhawar, R., Pollock, G., Liu, A., Jacobs, C., McCrary, B., Glassberg, J., & Curtis, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0340917
“It has also been demonstrated to have a possible anti-inflammatory effect [16].”
A Cross-Sectional Survey of Cannabis Use and Utility Among Patients Experiencing Dizziness
Elmi, P., Mavedatnia, D., Berberi, G., Lawrence, M. R., Tohmé, A., Hong, X., Lelli, D. A., & Tse, D. (2026) · Brain Sciences · doi:10.3390/brainsci16040360
“These discrepancies may contribute to variable side effect profiles, such as dizziness reported in some clinical trials [38–41].”
Complementary therapies for multiple sclerosis: Scoping review with evidence gap map
López‐Alcalde, J., Yan, Y., Canella, C., Barth, J., Steinemann, N., von Wyl, V., Baum, C., Bolt, S., Haegele-Link, S., Rettenmund, G., et al. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107243
“…al., 2010; Langford et al., 2013; Markov ` a et al., 2019; Mousavi-Shirazi-Fard et al., 2021; Novotna et al., 2011; Rezapour-Firouzi et al., 2013; Schimrigk et al., 2017; Tourbah et al., 2016; Vachov ´ a et al., 2014; Wade et al., 2004; Yeni et al., 2022; Zajicek et al., 2013; Zajicek et al.,…”
InfluentialSapkota, B., Dhakal, K., Sapkota, P., & Poudel, P. (2026) · Natural Product Communications · doi:10.1177/1934578x261451344
“132 The semi-synthetic THC derivative dronabinol, available as both a solution and a pill, has been approved by the FDA for treating chemotherapy-induced nausea in AIDS patients.”
Iešmantaitė, M., Usonis, L., Čeika, K., Šimoliūnas, E., Liudvinaitis, M., Soto-Arroyo, N., Moreno-Indias, I., Tinahones, F. J., Baltriukienė, D., & Mela, V. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01206-x
“Although some synthetic cannabinoid receptor agonists are used [26–28], most are associated with adverse effects [29].”
Abdalla, A., Sundar, P., & Hasoon, J. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36773-1.00006-4
The endocannabinoid system and its role in the treatment of neuropathic and chronic pain
Kallurkar, A., Skidmore, K. L., & Kaye, A. D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36773-1.00014-3
189Cannabis as medicine: established uses and known risks
Goldstein, F. J. (2026) · De Gruyter eBooks · doi:10.1515/9783111476162-012
Cannabinoids and therapeutic potential in neuropsychiatry
Ertenu, D. D., Papolu, A., Anderson, N., Wecker, E., Hauptman, A. J., & Salpekar, J. A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.030
Dronabinol for Neuropathic Pain in Palliative Care
Boogaerts, G., Rego, A., FREEMAN, H., Baumrucker, S. J., & Rashid, S. (2026) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2026.2718824
Metadata
- Authors
- Schimrigk, S., Marziniak, M., Neubauer, C., Kugler, E. M., Werner, G., & Abramov-Sommariva, D.
- Affiliations
- Klinikum Lüdenscheid (DE)
- Isar-Amper-Klinikum München-Ost (DE)
- Bionorica (Germany) (DE)
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 78
- Issue
- 5-6
- Pages
- 320-329
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- PMC
- PMC5804828
- OpenAlex
- W2765393731
- Cited by
- 136
- References
- 43
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 15 · 2023: 14 · 2022: 37 · 2021: 15 · 2020: 22 · 2019: 6 · 2018: 6
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- European Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer Vital
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- dronabinol, neuropathic pain, multiple sclerosis, cannabis-based treatment, long-term treatment safety, adverse drug reactions, drug addiction, pain intensity, risk-benefit ratio
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia, Dronabinol, Analgesics, Non-Narcotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.